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Calcific uraemic arteriolopathy (systemic calciphylaxis) is a rare, life-
threatening condition characterised pathologically by small-vessel 
calcification and ischaemic skin necrosis.[1] It occurs most frequently 
in the setting of end-stage renal diasease (ESRD) with secondary 
hyperparathyroidism and is more common in females than in males. 
In patients without advanced renal disease, it has been reported in 
cases of primary hyperparathyroidism, malignancy, alcoholic liver 
disease and connective tissue disease.[2]
The skin lesions of calciphylaxis typically develop suddenly and 
progress rapidly. Lesions may be singular or numerous, and generally 
occur on the legs. Intense pain is almost invariable. Early lesions of 
calciphylaxis manifest with dusky erythema, violaceous mottling 
or livedo reticularis, and progress to indurated papules, plaques 
or nodules. More developed skin lesions have an irregular outline 
that gives a stellate, purpuric appearance with central necrosis (see 
Fig. 1). Secondary infection of ulcerated skin lesions and subsequent 
fulminant sepsis are responsible for the significant morbidity and 
mortality associated with this condition.
Most cases have been described in patients with ESRD who 
are treated with renal replacement therapy (RRT) in the form of 
chronic dialysis or kidney transplantation. A cross-sectional study 
in patients on chronic haemodialysis reported a 4% prevalence of 
calciphy laxis.[3] Calciphylaxis complicating non-uraemic disorders is 
much rarer, with a systematic review published in 2008[2] reporting 
a total of only 36 cases. Of these patients, 10 had kidney disease as 
indicated by elevated serum creatinine concentrations; in 12 cases the 
serum creatinine level was not reported.
The pathogenesis of the condition remains uncertain. The term 
calciphylaxis was first coined by Hans Selye, who described an 
experimental rat model of metastatic calcification. His model seldom 
produced vascular calcification, however, and did not produce 
the skin necrosis so typical of the disease in humans.[4] Cutaneous 
vascular stenosis and thrombotic occlusion are separate processes 
that are both required to produce the lesions of calciphylaxis.[5] 
Vascular stenosis is caused by medial arteriolar calcification and 
subintimal fibrosis. Risk factors such as chronic inflammation, 
hyperparathyroidism, and drugs such as glucocorticoids and 
calcineurin inhibitors are frequently present in patients with ESRD 
and may lead to activation of nuclear factor κ-B (NFκB).[5] This 
promotes the transdifferentiation of vascular smooth-muscle cells to 
an osteogenic phenotype with subsequent vascular calcification. The 
vascular thrombosis occurs abruptly, precipitating the presentation 
of patients with the typical painful ischaemic skin lesions. Low flow 
rates through narrowed vessels, damage by subintimal fibrosis, and 
hypercoagulability from local and/or systemic inflammation and 
endothelial dysfunction may all contribute to vascular thrombosis.[5]
The diagnosis of calciphylaxis in patients being treated with 
RRT for ESRD is based mainly on the clinical presentation with the 
characteristic skin lesions.[6,7] A skin biopsy can worsen the skin 
lesions and need not be performed routinely. Obtaining a biopsy 
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specimen is recommended if the clinical features are not typical and 
when alternative diagnoses, such as warfarin skin necrosis or diabetic 
gangrene, are being considered.[6,7] Histopathological findings include 
medial calcification of small vessels, intimal proliferation, thrombosis, 
soft-tissue calcification, panniculitis and skin necrosis. Demonstrating 
calcifications in other vascular beds on plain radiographs is probably 
not useful in making the diagnosis of calciphylaxis, as this is a 
common finding in many patients on RRT.
Risk factors for developing calciphylaxis include female 
gender, white ethnicity, diabetes mellitus, obesity and secondary 
hyperparathyroidism.[8-11] Triggers such as the use of vitamin D prepa-
rations, calcium-based phosphate binders, corticosteroids, parenteral 
iron supplementation and warfarin have been postulated to initiate 
calcification in the ‘at-risk’ individual.[9,12]
The optimal treatment of the condition remains uncertain.[13] 
Principles of therapy include optimal wound care (sterile dressings, 
debridement, treating secondary infection), nutritional support 
in malnourished patients, and attempts to normalise serum cal-
cium and phosphate levels to lower the calcium-phosphate product. 
Parathyroidectomy has resulted in dramatic improvement in some 
cases, but the response is inconsistent and unpredictable.[14] Other 
treatment strategies include the use of non-calcium-based phosphate 
binders, bisphosphonates[13,15] and cinacalcet.[16] Intensified haemodi-
alysis, hyperbaric oxygen[17] and sodium thiosulphate, the antioxidant 
cation chelator[18] used as a component of multimodal therapy, may 
have contributed to the favourable outcome in some series.[19]
In this article we describe 19 patients with ESRD who presented 
with calciphylaxis, the majority of whom had received a renal trans-
plant. Patients were managed with multimodal therapy as available 
in our resource-constrained setting. This involved cessation of 
calcium-based phosphate binders and vitamin D, increased efforts 
to address the hyperphosphataemia and optimise haemodialysis, 
good wound care and antibiotics. A parathyroidectomy was per-
formed in selected cases and a single patient received bisphospho-
nate treatment.
Methods
The medical records of patients receiving RRT who were diagnosed 
with calciphylaxis in the Division of Nephrology at Tygerberg 
Hospital, Cape Town, South Africa, between 1990 and 2014 were 
reviewed. The records of all patients admitted to our RRT programme 
as well as those who have died are housed in the division. Only the 
clinicians who were directly involved in the routine clinical care of 
the patients described in this study accessed these records. Patient 
demographics, the clinical presentation, potential risk factors and 
laboratory results, including skin biopsy data, were extracted and 
recorded on standardised data capture sheets.
A clinical diagnosis of calciphylaxis was made in patients with 
ESRD who presented with the typical non-healing ischaemic skin 
lesions and who had no obvious alternative diagnosis. Diagnostic 
criteria have been proposed by Hiyashi[6] and require the following 
clinical criteria: a patient with ESRD; more than two painful and non-
treatable skin ulcers with concomitant painful purpura; and lesions 
on the trunk, extremities, or penis with concomitant painful purpura. 
A diagnosis can also be made when two of these three clinical features 
are present with typical histopathological findings.
Ethics approval
As this was a retrospective study, a waiver of individual informed 
consent was granted by the Health Research Ethics Committee at 
Stellenbosch University.
Results
Tygerberg Hospital is a 1 384-bed public sector teaching hospital. 
The number of patients on RRT is limited to ~70 patients on 
haemodialysis and 60 patients on peritoneal dialy sis owing to 
resource constraints. In addition, we follow up ~160 kidney 
transplant patients. Only patients who are suitable for kidney 
transplantation are accommodated, and peritoneal dialysis is 
usually the first treatment modality. Few diabetic patients are 
accommodated because of the frequent presence of multiple diabetic 
complications on presentation and poorer outcome following 
kidney transplantation. During the period 1990 - 2014, 937 new 
patients (53.0% female) were admitted to the renal replacement 
programme. Most of the patients (n=626, 66.8%) were of mixed 
ethnicity, while 151 (16.1%) were white, 141 (15.9%) black and 19 
(2.0%) Indian.
Nineteen patients (2.0% of those admitted to the RRT programme) 
were diagnosed with calciphylaxis (Table 1). This group had a median 
age of 34 years (interquartile range (IQR) 29 - 40) and consisted of 
13 females and 6 males. Most patients were white (n=12, 63.2%), 6 
were of mixed ancestry and only 1 was black. Three were obese (all 
female), but none was diabetic. Chronic glomerulonephritis was the 
most commonly reported cause of ESRD (11 patients).
All patients presented with typical painful, purpuric skin lesions. 
Ulceration was either present at presentation or developed later in the 
course of the disease. The lesions were typically indurated plaques 
and nodules (11 patients), were sometimes associated with livedo 
reticularis, and were confined to the legs below the knees in 73.7% of 
cases (Fig. 1). Two patients presented with proximal lesions (thighs, 
buttocks, abdomen) and 3 with both proximal and distal lesions. 
Most patients had radiographic evidence of vascular calcification 
(Fig. 2). Skin biopsy data were available in 18 patients, and in 13 the 
biopsy findings supported the diagnosis of calciphylaxis, revealing 
small-vessel calcification, panniculitis and, in one case, microvascular 
thrombosis (Figs 3 and 4).
The median time to diagnosis of calciphylaxis from the initiation 
of dialysis for the group was 51 months (IQR 12 - 96). Fifteen patients 
had previously received a renal transplant, with a median time to 
transplant of 29 months (IQR 4 - 60) after starting dialysis. In these 
patients, calciphylaxis was diagnosed at a median of 26 months 
(IQR 11 - 79) after transplantation. Six patients still had a functioning 
graft at the time of diagnosis.
Twelve patients (63.2%) had laboratory evidence of hyper para-
thyroidism (defined by serum intact parathyroid hormone concen-
trations >8.4 pmol/L, the upper limit of normal for our laboratory). 
The calcium-phosphate product was 4.4 mmol2/L2 in 10 of these 
patients. All patients were receiving our standard regimen of calcium-
based phosphate binders and vitamin D for the treatment of secondary 
hyperparathyroidism. The 6 patients with functioning kidney 
transplants were on our standard immunosuppression regimen of 
prednisone, azathioprine and cyclosporine. Five of the 15 previously 
transplanted patients had been pulsed with intravenous steroids 
(methylprednisolone) for graft rejection in the year preceding the 
diagnosis of calciphylaxis. Two patients had used warfarin in the 
past (Table 1, patients 5 and 7), 1 (patient 8) was on long-term 
warfarin treatment for previous pulmonary embolism at the time of 
the diagnosis of calciphylaxis, and 7 had received intravenous iron 
supplementation during the months leading up to their presentation 
with calciphylaxis.
Multimodal therapy for all patients included cessation of calcium-
based phosphate binders and vitamin D, strict dietary phosphate 
restriction, intensified haemodialysis (including more frequent 
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haemo dialysis), use of low-calcium dialysate, aggressive wound care 
(daily dressings, debridement) and antibiotic cover. Five patients had 
an urgent parathyroidectomy (patients 1, 12, 13, 14 and 16). One 
patient also received a course of intravenous bisphosphonates, and 
demonstrated good wound healing over a period of 2 months.
Four patients were considered to have been cured with aggressive 
multimodal therapy. Two of them (patients 7 and 10) subsequently 
died suddenly of cardiovascular causes, one within a month of disease 
stabilisation and the other after 22 months. The overall survival at 6 
months after the diagnosis of calciphylaxis was 31.6%, and at 1 year 
the survival rate was 15.8%. The median time from diagnosis to death 
for the 15 patients who died from complications of calciphylaxis was 
9 weeks (IQR 3 - 17). Most of the deaths were the result of severe 
sepsis related to infection of the necrotic skin lesions.
Discussion
Our study confirms that calciphylaxis is a relatively rare disease, 
affecting ~2% of our patients on RRT, and that it has a very poor 
prognosis. A particularly striking finding was that our white patients 
were much more frequently affected (7.9%) than our black patients 










(mmol/L) XR Bx Outcome
1 F 29 Mixed Chronic 
GN
Tx-HD Dist. 170 2.38 1.84 Y Y Died (sepsis)
2 F 25 White SLE HD-Tx Prox. 39.6 2.64 3.42 Y N Died (CNS 
bleed)
3 M 49 Mixed MHT PD-Tx-
HD
Dist. NA 2.44 2.11 NA Y Died (GI bleed)
4 F 31 White Reflux Tx-PD-
Tx
Prox. 98 2.59 2.48 Y Y Died (sepsis)
5 F 38 Black Chronic 
GN
Tx-PD Dist. 43.7 2.94 3.36 Y N Died (sepsis)
6 F 40 White Chronic 
GN
PD-HD Dist. 123 2.7 3.45 N Y Died (sepsis)
7 M 39 Mixed Chronic 
GN
HD-Tx Dist. 8 2.68 NA N Y Sudden death
8 F 42 White Reflux PD-Tx-
HD
Dist. NA 2.18 2.55 Y NA Died (sepsis)




Dist. 16 2.53 0.86 Y N Died (sepsis)
10 F 34 White ADPKD HD Dist. 44 1.99 5.31 Y N Died (MI)
11 F 34 Mixed Chronic 
GN
PD-Tx Dist. 16.4 2.47 1.5 Y Y Died (sepsis)




201+ 1.79 2.56 Y Y Alive




Dist. 201+ 2.11 3.21 Y N Alive




102 2.68 2.4 Y Y Died (sepsis)
15 M 38 White IN PD-Tx-
HD-Tx-
PD
Dist. 201+ 2.08 3.06 Y Y Died (sepsis)







NA 2.14 2.45 Y Y Died (sepsis)
17 M 58 Mixed ADPKD PD-Tx Dist. NA 1.74 3.06 Y Y Died (sepsis)
18 M 45 White Reflux Tx-PD Dist. NA NA NA NA Y Died (sepsis)
19 F 14 White Chronic 
GN
Tx-PD Dist. NA 2.52 2.02 N Y Died (sepsis)
Renal dx = primary renal disease; Chronic GN = chronic glomerulonephritis; SLE = systemic lupus erythematosus; MHT = malignant hypertension; Reflux = reflux nephropathy; ADPKD = 
autosomal dominant polycystic kidney disease; IN = interstitial nephritis; Modality = prior and current RRT modalities; HD = haemodialysis; Tx = kidney transplant; PD = peritoneal dialysis; 
Dist. = distal; Prox. = proximal; PTH = parathyroid hormone; Ca = total corrected calcium; PO4 = phosphate; XR = vascular calcification present on X-ray; Bx = vascular calcification present on 
skin biopsy; Y = yes; N = no; NA = data not available; CNS = central nervous system; GI = gastrointestinal; MI = myocardial infarction.
*Presented with ESRD before initiating RRT.
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(0.7%) and those of mixed ethnicity (1.0%). This has also been 
reported by other investigators.[8,11]
The patients described in this study had several potential risk factors 
for calciphylaxis,[9,10] including female gender and derangements of 
calcium and phosphate metabolism. Trigger factors such as the use of 
calcium-based phosphate binders, parenteral iron supplementation 
and warfarin may also have contributed to the development of 
calciphylaxis.[5,20]
An unusual feature of our study is the fact that most of the patients 
had been renal allograft recipients. It must be pointed out that in our 
resource-limited setting only patients suitable for transplantation 
are admitted to our renal replacement programme. Systemic 
corticosteroid use is a risk factor associated with calciphylaxis,[10] and 
it is therefore possible that episodes of acute rejection and the pulse 
steroids used to treat these precipitated the condition in some of these 
transplanted patients.
The very high mortality rate is another striking feature of the 
study, as is the very short time from diagnosis to death. While the 
cause of death in patients 2, 3 and 7 could not be ascribed directly to 
calciphylaxis, we nevertheless found the prognosis to be much worse 
than previously reported. Weenig et al.[10] reported a 1-year survival 
rate of 45.8% in their study of 64 patients, which included patients 
on dialysis as well as patients without ESRD. The 48 dialysis patients 
had a 1-year survival rate of 29%. Some authors have emphasised 
the distribution of the lesions, noting that patients with proximal 
skin lesions have a far worse prognosis than those with only distal 
lesions.[1,21] Only 5 of our 19 patients fell into this category, but we 
nevertheless had very poor overall outcomes.
Treatment options for calciphylaxis generally remain unsatisfactory 
and there are no randomised trials available to guide therapy.[13] The 
high cost of non-calcium-based phosphate binders, cinacalcet and 
sodium thiosulfate, as well as limited access to hyperbaric oxygen 
therapy, restricted our use of these treatment modalities. In all patients 
attempts were made to normalise calcium and phosphate homeostasis by 
stopping the use of calcium carbonate and vitamin D, switching patients 
to an intensified haemodialysis regimen and using bisphosphonates (one 
case). Good wound care, including surgical debridement, was provided 
Fig. 4. Skin biopsy demonstrating circumferential microvascular calcification 
and an organised thrombus within the vascular lumen (Von Kossa stain, 
original magnification ×200).
Fig. 2. Radiographs of the hands demonstrating extensive vascular calci­
fication.
Fig. 1. Ischaemic skin necrosis with the typical irregular outline. Fig. 3. Skin biopsy demonstrating circumferential microvascular calci­
fication. Note necrosis of the adjacent subcutaneous tissue (H&E, original 
magnification ×200).
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and antibiotics were commenced at the earliest sign of local or systemic 
infection. A parathyroidectomy was performed on 5 patients; this 
seemed to contribute to wound healing in 2 cases.
Conclusions
Our experience with calciphylaxis confirms that it has a particularly 
poor prognosis. The high mortality rate also seems to apply to 
patients with distal limb lesions, which had been thought to confer a 
more favourable prognosis. In our cohort of patients, transplantation 
and the pulse steroids administered to treat episodes of acute 
rejection may have contributed to the development of calciphylaxis. 
It should always be considered in the differential diagnosis of painful 
skin lesions in the dialysis or transplant patient.
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